Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 33 Show results per page	View Search Criteria \| Help With Results

Last Modified: 8/9/2007 First Published: 10/1/2002


1.		Phase III Randomized Study of Fluorouracil, Epirubicin, and Cyclophosphamide Versus Docetaxel, Epirubicin, and Cyclophosphamide in Women With Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Other				LMU-ADEBAR EU-20221, NCT00047099

Last Modified: 12/20/2006 First Published: 2/21/2003


2.		Phase III Randomized Study of Neoadjuvant Releasing Factor Agonist Therapy and Antiandrogen Therapy With or Without Docetaxel And Estramustine in Patients With Locally Advanced Prostate Cancer or With A High Risk of Relapse

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 80				Other				FRE-FNCLCC-GETUG-12/0203 EU-20238, NCT00055731

Last Modified: 10/15/2008 First Published: 8/24/2003


3.		Phase III Randomized Study of Goserelin for the Reduction of Premature Ovarian Failure in Women With Stage I-IIIA Hormone Receptor-Negative Breast Cancer Undergoing Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 to 49				NCI				SWOG-S0230 CALGB-40401, ECOG-S0230, NCT00068601, IBCSG-34-05, EUDRACT-2006-002600-33, EU-20632

Last Modified: 5/12/2008 First Published: 2/18/2005


4.		Phase III Randomized Study of Hormonal Therapy and Docetaxel Versus Hormonal Therapy Alone in Patients With Metastatic Prostate Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				FRE-FNCLCC-GETUG-15/0403 NCT00104715

Last Modified: 10/16/2008 First Published: 1/25/2006


5.		Phase III Randomized Study of Androgen Suppression (AS) and Radiotherapy (RT) Versus AS and RT Followed by Docetaxel and Prednisone in Patients With Localized, High-Risk Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0521 RTOG-0521, NCT00288080

Last Modified: 10/17/2008 First Published: 5/11/2006


6.		Phase III Randomized Study of Zoledronate in Preventing Osteoporosis and Associated Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiotherapy and Luteinizing Hormone-Releasing Hormone Agonist Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				18 and over				NCI				RTOG-0518 0518, RTOG-0518, NCT00329797


7.		External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Not specified				Other				2003-0819 NCT00388804

First Published: 1/5/2007


8.		Phase III Randomized Study of Adjuvant Radiotherapy With Versus Without Concurrent Goserelin in Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				FRE-FNCLCC-GETUG-16/0504 EU-20668, EUDRACT-2005-005165, NCT00423475

Last Modified: 10/11/2008 First Published: 1/25/2007


9.		Phase III Randomized Study of Radical Prostatectomy With Versus Without Neoadjuvant Chemohormonal Therapy Comprising Docetaxel and Androgen-Deprivation Therapy With Leuprolide Acetate or Goserelin in Patients With High-Risk, Clinically Localized Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-90203 CALGB-90203, NCT00430183

Last Modified: 5/7/2007 First Published: 1/19/2007


10.		Phase III Randomized Study of Goserelin for Prevention of Premature Ovarian Failure in Premenopausal Women Undergoing Chemotherapy for Stage I-III Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				Not specified				Other				CRUK-OPTION EUDRACT-2004-000133-11, CRUK-BR0402, ISRCTN84856516, EU-20680, NCT00427245

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute